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Abstract
Screening for microbial secondary metabolites (SMs) has attracted the attention 
of the scientific community since 1940s. In fact, since the discovery of penicillin, 
intensive researches have been conducted worldwide in order to detect and identify 
novel microbial secondary metabolites. As a result, the discovery of novel SMs has 
been decreased significantly by using traditional experiments. Therefore, searching 
for new techniques to discover novel SMs was one of the most priority objectives. 
However, the development and advances of omics-based techniques such as metabo-
lomics and genomics have revealed the potential of discovering novel SMs which were 
coded in the microorganisms’ DNA but not expressed in the lab media or might be 
produced in undetectable amount by detecting the biosynthesis gene clusters (BGCs) 
that are associated with the biosynthesis of secondary metabolites. Nowadays, the 
development and integration of gene editing tools such as CRISPR-Cas9 in metabolo-
mics provide a successful platform for the identification and detection of known and 
novel SMs and also to increase the production of SMs.
Keywords: secondary metabolites, metabolomics, genomic, CRISPR-Cas9, secondary 
metabolites identification, production of secondary metabolites, microorganisms, 
gene editing
1. Introduction
The term secondary metabolites (SMs) was first mentioned in 1891 by A. Kossel. 
Microbial secondary metabolites have attracted the scientific world’s attention, 
since the discovery of penicillin in 1940s. After that, the identification and char-
acterization of SMs have reached the highest level between 1940s and 1960s, and 
this period is called as “the golden era of SMs discovery” [1, 2]. A lot of compounds 
have been characterized and reported during the golden era and are still utilized 
till now. Unfortunately, the discovery of approved novel chemical scaffolds of 
secondary metabolites has significantly decreased after the golden era [1]. The 
possible explanation of the decreasing in the SMs’ identification might be due to 
the following: (1) using the biosynthetic modules that are used for SMs’ production 
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by many bacteria, (2) focusing on some specific group of microorganisms such as 
actinobacteria, resulting in the isolation and identification of known compounds, 
and (3) almost 1% of the microbial community can be cultured in the laboratory [2] 
due to the difficulty in identifying their optimal medium compositions, resulting in 
the majority of SMs not being identified.
Microbial secondary metabolites play significant roles in our life. Because of SMs’ 
unusual chemical structures, the microbial secondary metabolites show a variety of 
biological activities such as antimicrobial agents, antitumor agents, enzyme inhibi-
tor, immunosuppressive agents, antiparasitic agents, herbicides, anthelmintic and 
food industry, etc. For instance, one of the huge successes in human medicine is the 
discovery of immunosuppression, such as cyclosporine A, which plays a significant 
role in establishing the organ transplant field.
All biochemical reactions carried out by organisms are called as metabolism and all 
products resulting from metabolism are called as metabolites. As a result of metabo-
lism reactions, organisms produce primary and secondary metabolites. Primary 
metabolites are found in all living cells that are able to divide, while secondary metab-
olites are present only incidentally and do not affect the organism’s life immediately. 
Nowadays, over 2,140,000 secondary metabolites (SMs) have been identified based 
on their vast diversity in function, structure, and biosynthesis (Table 1) [3]. The 
major sources of SMs are plants (about 80%) and microorganisms. Among microor-
ganisms, bacteria, especially actinobacteria, and fungi have been reported to produce 
the majority of SMs that have been identified till now [4].
Microbial secondary metabolites (SMs) such as antibiotics, alkaloids, toxins, 
pigments, growth hormones, antitumor agents, and others are low molecular mass 
products that are produced by microorganisms, usually during the late growth 
phase. In fact, microbial secondary metabolites are not essential for the growth and 
development of microorganisms that produce them but are associated with some 
other functions such as competition, interactions, defense, and others [3, 5].
The development and advances of omics-based techniques such as genomics, 
metabolomics, proteomics, and trascriptomics have revealed that microorganisms 
have the potential to produce more secondary metabolites than were originally 
expected [6, 38]. These products are often coded by clustered genes present on 
the chromosomal DNA and rarely on plasmid DNA. In fact, most of these new 
Source All known compounds Bioactive
Plant kingdom 600,000–700,000 150,000–200,000
Microbes Over 50,000 22,000–23,000
Higher plants 500,000–600,000 ~100,000
Animal kingdom 300,000–400,000 50,000–100,000
Protozoa Several hundreds 100–200
Vertebrates 200,000–250,000 50,000–70,000
Marine animals 20,000–25,000 7000–8000
Invertebrates ~100,000 NA
Algae, lichens 3000–5000 1500–2000
Insects, worms 8000–10,000 800–1000
NA—data not available.
Source: Bérdy [4].
Table 1. 
Approximate number of identified natural metabolites.
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SMs have been predicted only by using bioinformatics analysis, which analyzes 
the putative SMs gene clusters in a sequenced genome. This is because, all of the 
new revealed SMs are not produced naturally under the lab conditions, or even 
though they are produced, this in very low amount that the traditional detection 
techniques are unable to detect them [7, 8]. Metabolomics approach aims to discover 
and characterize secondary metabolites in natural or engineered biosystems, and it 
can measure as many low molecular weight compounds as possible. Metabolomics-
based technologies such as mass spectrometry (MS) and nuclear magnetic reso-
nance (NMR) have been identified as significant analytical methods to detect SMs 
produced under specific conditions [9]. The present chapter provides an overview 
of present-day metabolomic and genetic engineering approaches for secondary 
metabolites’ enhancement and identification [43].
2. Genomic for screening and enhancement of SMs
2.1 Gene editing for metabolites discovery
Biosynthesis gene clusters (BGCs) are the genes associated with the biosynthesis 
of secondary metabolites. These BGCs include all genetic information necessary 
for SMs’ biosynthesis, assembly, modification, and regulation of their export 
and transport [43]. Microorganisms’ genome contains variety of cryptic or silent 
genes that are responsible for the production of secondary metabolites but are not 
expressed under laboratory conditions. It has been reported that most BGCs remain 
silent and cannot be fully expressed under standard laboratory conditions. These 
silent BGCs are potentially significant in the discovery of novel SMs [10–12, 43].
Due to the development of genomic and bioinformatic field, we are able to access 
extensive sequencing data and genetic information and enable genome mining of 
relevant BGCs with the potential for valuable SM production [13]. Therefore, bio-
synthetic biology and genetic engineering tools are now utilized for identification 
of novel BGCs. In fact, genetic engineering is now widely used and moving beyond 
traditional tools, which has opened a new era in the detection of novel secondary 
metabolites [16]. Genetic engineering for the production of SMs can be carried out 
in heterologous as well as homologous host. In fact, gene manipulation in heterolo-
gous host enables the activation of biosynthesis gene clusters (BGCs) obtained from 
unculturable organisms, whereas gene manipulation in homologous host allows the 
retention of all natural factors essential for the production of secondary metabolites 
[14]. While there is no single approach that will work for all genes of interest, a 
variety of techniques have been developed to induce the expression of these genes.
In fact, several genome techniques have emerged and are utilized in the metabo-
lomic production field, including transcriptional activator-like effector nucleases 
(TALENs), zinc finger nucleases (ZFNs), and clustered regulatory interspaced 
short palindromic repeat (CRISPR-Cas9) [45, 46]. Each genome engineering tech-
nology has its own advantages and disadvantages (Table 2). For instance, ZFNs and 
TALENs have been successfully utilized in various microbes but still have limitation 
which includes the difficulty to engineer them [44]. Recently, CRISPR-Cas9 has 
been reported to be a significant and promising genome editing technology in the 
discovery and production of SMs [14, 16, 23].
2.1.1 Gene cloning
Direct cloning of the entire BGCs into the heterologous host is the most general 
and widely used approach for the activation of silent BGCs. Nowadays, many new 
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cloning tools have been introduced, including Cas9-assisted targeting of chromo-
some segments (CATCH), transformation-assisted recombination (TAR), and 
TAR-CRISPR [15, 17, 18]. Basically, gene cloning steps include: determining the 
suitable heterologous host, cloning of the target BGC, transfer of the BGC into the 
chosen host, expression in chosen host system, and optimization of production.
CRISPR/Cas9 Zinc finger 
nucleases (ZFNs)
Transcription factor-
like effector nucleases 
(TALENs)
1 Protein 
engineering 
steps
It does not require 
protein engineering 
steps, very simple to test 
multiple gRNA
It requires complex 
steps to test gRNA
TALENs need protein 
engineering steps to test 
gRNA
2 Mode of 
action
It works by including 
double-strand breaks in 
target DNA or single-
strand DNA nicks (Cas9 
nickase)
It can induce 
double-strand 
breaks in target 
DNA
Induces DSBs in target 
DNA
3 Cloning Not Required Required Required
4 Structural 
proteins
CRISPR consists of 
single monomeric 
protein and chimeric 
RNA
ZFNs work as 
dimeric and only 
protein component 
is required
TALENs also work as 
dimeric and require protein 
component
5 Mutation rate Low mutation rate has 
been observed
High mutation rate 
has been observed 
in plants
Mutation rate is high as 
compared to CRISPR
6 Components crRNA, Cas9 proteins Zn-finger 
domains, 
nonspecific FOKI 
nuclease domain
Zn-finger domains, 
nonspecific folk nuclease 
domain
7 Length 
of target 
sequence 
(bp)
20–22 18–24 24–59
8 Target 
recognition 
efficiency
High High High
9 Level of 
experiment
Easy and very fast 
procedure
Complicated 
procedure and 
need for expertise 
in protein 
engineering
Relatively easy procedure
10 Methylated 
DNA cleavage
It can cleave methylated 
DNA in human cells. 
This aspect is of special 
concern for plants as 
this has not been much 
explored
Unable to do so There are many question 
marks upon the capacity 
of TALENs to perform 
methylated DNA cleavage
11 Multiplexing This is the main 
advantage of CRISPR, 
and several genes can 
be edited at same time. 
Only Cas9 is needed
Highly difficult 
to achieve this 
through ZFNs
Very difficult to obtain 
multiplexed genes by 
means of TALENs. Because 
it needs separate dimeric 
proteins specific for each 
target
Table 2. 
Different genomic engineering techniques used in Metabolomic.
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Cas9-assisted targeting of chromosome segments (CATCH) is a cloning tech-
nique that utilizes the CRISPR-Cas9 gene editing system for direct BGCs cloning 
into the host. Comparing with traditional cloning tools such as PCR and restricted 
enzymes, CATCH is predicted to become a useful molecular tool for direct clon-
ing of large gene clusters. Transformation-assisted recombination (TAR) has been 
used for cloning of large BGCs for about decades. However, the TAR approach 
is associated with a low cloning efficiency, which means it requires screening of 
hundreds of colonies to detect few positive clones [15, 18]. To address this chal-
lenge, TAR and CRISPR-Cas9 have been coupled resulting in a new approach 
called TAR-CRISPR [18]. By coupling TAR with CRISPR, a significant increase of 
the clone efficiency has been reported. Comparing with traditional TAR cloning, 
the advantages of TAR-CRISPR are that the positive clones could be achieved 
with secondary screening and lesser manpower and also it does not require a high 
experience of working with yeast [18]. In fact, the TAR-CRISTAR cloning will 
allow for the development of BGC cloning and SM production in the future.
2.1.2 Gene refactoring
Gene refactoring or replacement is useful not only in BGCs’ activation but 
also for novel SMs’ discovery. In fact, several silent BGCs have been refactored by 
replacing the BGC promoter to yield natural products such as secondary metabo-
lites [19–22].
Another new tool in gene refactoring is multiplexed CRISPR-Cas9- and 
transformation-associated recombination (TAR)-mediated promoter engineering 
method (mCRISTAR) [23]. This new tool combines the advantages of the CRISPR-
Cas9 system and TAR. It is different than the TAR-CRISPR that was discussed 
earlier. Comparing with TAR-CRISPR, which is a yeast-based method, basically 
mCRISTAR uses CRISPR-Cas9 to break the double-stranded in the promoter region 
of the BGC, and the fragments produced are reassembled by TAR with synthetic 
gene-cluster-specific promoter cassettes. Another gene refactoring tool that has 
aided in the faster cloning and refactoring of BGCs is the direct pathway cloning 
(DiPaC). Direct pathway cloning (DiPaC) depends on PCR amplification and in 
vitro DNA assembly for biosynthesis gene cluster capture and their expression. 
DiPaC was recently employed for the capture of biosynthesis gene cluster, which is 
small in size, followed by their activation and expression of novel natural products 
[24]. DiPaC was also able to successfully clone mid and large size of BGC [24].
2.1.3 Gene insertion or deletion
A large number of researches have documented the effect of gene knockout/in 
on BGC expression or levels of SM production. However, conventional methods 
of gene editing are time-intensive, while CRISPR-Cas9-based approach allows for 
much faster and efficient gene editing [25]. The emergence of CRISPR-Cas9 has 
opened up a new era in gene editing opportunities [26]. Recently, CRISPR gene 
editing approach has been used to insert promoter in order to activate microor-
ganisms’ SMs’ production [27].
Nowadays, CRISPR-Cas9 is used to introduce promoter at multiple BGCs, and 
at the same time, resulting in the activation of BGCs followed by the production of 
SMs [27]. Multiplexed site-specific genome engineering (MSGE) was also used for 
multiple BGCs’ editing [28]. MSGE has led to a significant increase in the secondary 
metabolites’ production.
While, gene editing approaches provide a significant platform to manipulate the 
genetic machinery of microbes toward the production of novel, natural secondary 
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metabolites, the identification of secondary metabolites is also equally important. 
Metabolomics plays a significant role in the identification and characterization of 
secondary metabolites produced by native or genetically modified microorganisms.
2.2 Identification and characterization of secondary metabolites
Unlike all omics techniques, metabolomics often requires a broad array of 
instrumentation such as coulometric array detectors for detecting redox com-
pounds, fluorescent spectrometers for detecting aromatic compounds, and ELSD 
for detecting lipids, whereas genomics, proteomics, or transcriptomics measure-
ments are often conducted by a single instrument.
In general, microbial secondary metabolites’ investigation is mainly conducted 
in two different approaches, the targeted and untargeted metabolites’ identification 
[29]. Targeted metabolites’ experiments aim to detect a specific group of compounds 
(about 20 compounds) that are already identified. Whereas, untargeted secondary 
metabolites’ investigation aims to detect and identify a large scale of metabolites that 
are produced by microorganisms, including known and novel metabolites [30].
Over the past decade, two general technologies have emerged as the primary tools 
in metabolomics, the nuclear magnetic resonance (NMR) spectroscopy and mass 
spectrometry (MS) [31]. Some of the common MS-based analyses are (GC-MS), 
(CE-MS), and (LC-MS) [32, 42]. These high-throughput tools provide a broad cover-
age of many classes of secondary metabolites, including amino acids, lipids, sugars, 
organic acids, and others.
2.2.1 Detection of secondary metabolites
Mass spectrometry (MS) is a technique that measures the mass-to-charge ratio 
of molecule. The principle of chromatography is to detect the retention time of the 
constituents that travel at different speeds under a specific condition. Therefore, 
various constituents take different time to pass from the inlet to the detector of the 
chromatography system [31].
Nuclear magnetic resonance (NMR) spectroscopy principle is based on using 
the magnetic properties of atomic nuclei to determine the chemical and physical 
properties of atoms or molecules in which they are contained. NMR’s mechanism of 
action is that the magnetic nuclei in magnetic field absorb, resulting in reemitting 
of electromagnetic radiation at a specific resonance frequency depending on the 
magnetic properties of the isotope of atom as well as the strength of the magnetic 
field [31].
Both MS and NMR can be utilized to identify targeted and untargeted metabo-
lomics. In fact, MS and NMR are often complementary techniques to each other. 
While NMR can be used to differentiate between structural isomers, MS provides 
information on the formula of the molecule [33]. Comparing to NMR, mass 
spectrometry is more sensitive and is able to detect a large scale of metabolites. 
On the other hand, nuclear magnetic resonance (NMR) spectroscopy is highly 
quantitative and reproducible. Unlike MS, NMR requires a larger sample amount 
for analysis [34, 35].
2.2.2 Data analysis
In fact, the complexity and huge amount of information that are obtained from 
either NMR spectroscopy or MS are considered to be one of the major challenges 
in metabolomics experiments [38]. The extraction of the important information 
that is generated by MS or NMR spectroscopy depends on using computer software 
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in order to organize the vast amount of data [34]. First, the row data acquired 
from the NMR spectroscopy or MS must be first converted into computer formats 
compatible with software packages. In fact, the goal of metabolomics data analysis 
is to compare and identify the differences between hundreds or thousands of SMs. 
It is unpractical to visualize changes between groups of metabolites by analyzing 
metabolites individually; therefore, univariate and multivariate statistical tech-
niques can then be used to interpret the data. One of the most widely used statistical 
methods is the principal component analysis (PCA) [33, 36, 37]. By using PCA, 
the data can be simplified without losing their main features. Generally, the PCA 
principle is based on reducing the dimensionality of the data set, while keeping 
characteristics participating most to the variance. In fact, PCA provides informa-
tion on multivariate differences among metabolites. It is usually conducted at the 
early stages of data analysis.
However, different univariant statistical tests can be used to analyze isolated 
metabolites such as ANOVA, nonparametric Wilcoxon signed-rank test, Kruskal-
Wallis test, and the parametric Student’s t-test [39]. Furthermore, other univariant 
analysis can be used to validate the analysis such as false discovery rate calculations 
or Bonferroni correction [39].
2.2.3 Metabolites’ identification
Due to the development of various bioinformatics software, most of metabolites 
can be identified. Two types of metabolites’ identification are applied, including 
(a) putative identification and (b) definitive identification [38]. In putative identi-
fication, one or two molecular properties are utilized for identification. However, 
in definitive identification, two properties such as the retention time and accurate 
mass and/or fragmentation mass spectrum and/or NMR spectrum are used and 
compared with authentic chemical standard. Comparing to putative identification, 
definitive identification is a more accurate form of identification, while definitive 
identification uses the authentic chemical standard. Usually, the definitive identifi-
cation is performed after the putative identification.
Nowadays, a variety of different metabolomics’ databases are available 
online [40, 41].
Some are spectral-based databases as well as chemical structure-based databases 
for metabolites’ identification. Generally, spectra generated during analysis are 
compared with reference compounds in databases, and then similarity is assigned to 
each other. Even though, metabolome databases are updated daily, still significant 
numbers of secondary metabolites in biological system are unidentified.
Some of the common databases used in nuclear magnetic resonance (NMR) 
spectroscopy are METLIN (http://metlin.scripps.edu), the Human Metabolome 
Database (HMDB, http://www.hmdb.ca), and Biological Magnetic Resonance 
Databank (http://www.bmrb.wisc.edu/metabolomics/), whereas commonly used 
databases for mass spectrometry are NIST (http://www.nist.gov/srd/nist1a.htm), 
MassBank (http://www.massbank.jp), the Golm Metabolite Database (GMD, http://
csbdb.mpimp-golm.mpg.de/csbdb/gmd/gmd.html), METLI, and MMCD (http://
mmcd.nmrfam.wisc.edu) [40].
3. Conclusion
Microorganisms are a rich source of secondary metabolites which have 
significant pharmaceutical, biomedical, and food applications. Nowadays, the 
development and integration of gene editing tools, especially CRISPR-Cas9 
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(gene cloning, gene refactoring, and gene insertion or deletion) in metabo-
lomics, provide a successful platform for the identification and detection of 
known and novel SMs and also to increase the production of SMs. However, 
there are still some challenges associated with the application of metabolomics 
and gene editing, including that complete identification of novel SMs requires a 
combination of different methods which also result in increase in the screening 
cost. Thus, a comprehensive and sensitive technique is the need of hour, which 
has the ability to provide comprehensive information of any SMs under any 
conditions. Also, the off-target effect of CRISPR-Cas9 is a significant problem. 
However, the integration of metabolomics and CRISPR-Cas9-based gene editing 
tools may improve the efficiency of microbial secondary metabolites’ discovery.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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